Literature DB >> 3122700

Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output.

R N Golden1, S P Markey, E D Risby, M V Rudorfer, R W Cowdry, W Z Potter.   

Abstract

The effects of antidepressant treatment on noradrenergic function were studied in 27 patients with a major affective disorder. Twenty-four-hour urinary excretion of 6-hydroxymelatonin and "whole-body norepinephrine (NE) turnover," ie, 24-hour urinary output of NE and its major metabolites 3-methoxy-4-hydroxyphenylglycol, vanillylmandelic acid, and normetanephrine, were measured before and after treatment with the tricyclic desipramine hydrochloride, the aminoketone bupropion hydrochloride, the nonselective monoamine oxidase (MAO) inhibitor tranylcypromine sulfate, and the specific MAO type A inhibitor clorgiline. 6-Hydroxymelatonin excretion increased following antidepressant treatment, while at the same time whole-body NE turnover was reduced. These findings support the hypothesis that antidepressant therapy increases noradrenergic "efficiency," in that functional output, as measured by 6-hydroxymelatonin, is maintained while total NE production is decreased.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3122700     DOI: 10.1001/archpsyc.1988.01800260060008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  12 in total

1.  Brain mechanisms of stress and depression in coronary artery disease.

Authors:  J Douglas Bremner; Carolina Campanella; Zehra Khan; Negar Fani; Nicole Kasher; Sarah Evans; Collin Reiff; Sanskriti Mishra; Stacy Ladd; Jonathon A Nye; Paolo Raggi; Viola Vaccarino
Journal:  J Psychiatr Res       Date:  2018-11-22       Impact factor: 4.791

Review 2.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

3.  Melatonin responses to clonidine and yohimbine challenges.

Authors:  S H Kennedy; W Gnam; E Ralevski; G M Brown
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

4.  Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3).

Authors:  John J Mooney; Jacqueline A Samson; John Hennen; Kathleen Pappalardo; Nancy McHale; Jonathan Alpert; Martha Koutsos; Joseph J Schildkraut
Journal:  J Psychiatr Res       Date:  2007-08-28       Impact factor: 4.791

5.  Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression.

Authors:  J Douglas Bremner; Meena Vythilingam; Chin K Ng; Eric Vermetten; Ahsan Nazeer; Dan A Oren; Robert M Berman; Dennis S Charney
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

Review 6.  Animal models and treatments for addiction and depression co-morbidity.

Authors:  Neil E Paterson; Athina Markou
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 7.  Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap.

Authors:  Roger S McIntyre; Natalie L Rasgon; David E Kemp; Ha T Nguyen; Candy W Y Law; Valerie H Taylor; Hanna O Woldeyohannes; Mohammad T Alsuwaidan; Joanna K Soczynska; Byungsu Kim; Maria T Lourenco; Linda S Kahn; Benjamin I Goldstein
Journal:  Curr Diab Rep       Date:  2009-02       Impact factor: 4.810

8.  Neuroimmune endocrine effects of antidepressants.

Authors:  Marco Antonioli; Joanna Rybka; Livia A Carvalho
Journal:  Neuropsychiatr Dis Treat       Date:  2012-02-07       Impact factor: 2.570

9.  Pilot investigation of the circadian plasma melatonin rhythm across the menstrual cycle in a small group of women with premenstrual dysphoric disorder.

Authors:  Ari Shechter; Paul Lespérance; N M K Ng Ying Kin; Diane B Boivin
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

10.  Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial.

Authors:  Frederick W Reimherr; Dawson W Hedges; Robert E Strong; Barrie K Marchant; Erika D Williams
Journal:  Neuropsychiatr Dis Treat       Date:  2005-09       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.